X
21Sep

Reminder-Bio-Rad Geenius HIV 1/2 Implemented

0 Comments | | Return |

CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

Reminder- Re-entry Webinar

Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...

Read More >

Update on CTS Implementation of the Grifols Procleix Ultrio Elite Assay

In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...

Read More >

CTS Charlotte Implements New Laboratory Information System

On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...

Read More >

Preparing for Hurricane Florence

As the US coast prepares for Hurricane Florence to make landfall, we have received importan...

Read More >

Reminder-Confirmatory Algorithm and Assay Changes Effective September 30, 2019

On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...

Read More >

CTS to Implement Donor HLA testing on the Stratec Gemini Instrument

On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...

Read More >

Subscribe here to receive CTS updates!

Name